Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial ; volume:25 ; number:1 ; day:21 ; month:5 ; year:2024 ; pages:1-11 ; date:12.2024
The journal of headache and pain ; 25, Heft 1 (21.5.2024), 1-11, 12.2024

Creator: Lipton, Richard B.
Nahas, Stephanie J.
Pozo-Rosich, Patricia
Bilchik, Tanya
McAllister, Peter
Finnegan, Michelle
Liu, Yingyi
Chalermpalanupap, Natty
Dabruzzo, Brett
Dodick, David W.

Contributor: SpringerLink (Online service)

DOI: 10.1186/s10194-024-01783-6

URN: urn:nbn:de:101:1-2407311013543.871779629169

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:46 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Lipton, Richard B.
Nahas, Stephanie J.
Pozo-Rosich, Patricia
Bilchik, Tanya
McAllister, Peter
Finnegan, Michelle
Liu, Yingyi
Chalermpalanupap, Natty
Dabruzzo, Brett
Dodick, David W.
SpringerLink (Online service)

Other Objects (12)

Graffiti | Streetart

"week!"

Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial

Day of the week to tweet: a randomised controlled trial

Illustration

Week-End

Illustration

Week-End

Illustration

Week-End

Illustration

Week-End

Illustration

Week-End

Illustration

Week-End

Illustration

Week-End

Illustration

Week-End

Illustration

Week-End

Graffiti | Streetart

"week!"

Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial

Day of the week to tweet: a randomised controlled trial

Illustration

Week-End

Illustration

Week-End

Illustration

Week-End

Illustration

Week-End

Illustration

Week-End

Illustration

Week-End

Illustration

Week-End

Illustration

Week-End

Illustration

Week-End

Graffiti | Streetart

"week!"

Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial

Day of the week to tweet: a randomised controlled trial

Illustration

Week-End

Illustration

Week-End

Illustration

Week-End

Illustration

Week-End

Illustration

Week-End

Illustration

Week-End

Illustration

Week-End

Illustration

Week-End

Illustration

Week-End

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

"week!"

Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial

Day of the week to tweet: a randomised controlled trial

Week-End

Week-End

Week-End

Week-End

Week-End

Week-End

Week-End

Week-End

Week-End

"week!"

Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial

Day of the week to tweet: a randomised controlled trial

Week-End

Week-End

Week-End

Week-End

Week-End

Week-End

Week-End

Week-End

Week-End

"week!"

Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial

Day of the week to tweet: a randomised controlled trial

Week-End

Week-End

Week-End

Week-End

Week-End

Week-End

Week-End

Week-End

Week-End

Related objects

Reset password